Since 2012, due to the expiration of some patents and fierce market competition, Pfizer's sales of several best-selling products have declined. In 2016, 11 of the 18 major products Pfizer sold worldwide had negative growth rates. After careful analysis, it was found that three products had a rapid growth in sales last year, which saved Pfizer's overall performance. In 2016, Pfizer ranked second in the list of top ten multinational pharmaceutical companies, with total sales revenue of US$52.8 billion and growth rate of 8%.

Sitting on 8 broken $1 billion bestsellers

The pneumonia vaccine Pei series declined in 2016, from US$6.245 billion in 2015 to US$5.718 billion, a decrease of 8.44%, but according to forecasts issued by Evaluate Pharma, a world-renowned pharmaceutical market research institute, to 2020 In the year, Pei's 13-valent vaccine will remain the world's best-selling vaccine product.

The performance of the new generation of calcium channel regulator Lerica is relatively stable, with 2016 sales of 4.966 billion US dollars, an increase of 2.65%.

In 2016, Pfizer's most eye-catching variety was Ibrance, the new drug for breast cancer, the first CDK4/6 inhibitor listed worldwide. In February 2015, Pabotini was approved by the FDA to treat HR+/HER2- breast cancer first-line treatment to second-line treatment. The expansion of the patient population has directly benefited the market. The product sales in 2016 exceeded $2 billion. The year-on-year increase of nearly 720 million US dollars in 2015 was nearly 200%.

It is also worth mentioning that Xeljanz (tofatinib citrate), the world's first FDA-approved daily oral JAK inhibitor, nearly doubled sales in 2016, and the European Medicines Agency (EMA) The drug has been approved for monotherapy or combined methotrexate combination therapy for the treatment of rheumatoid arthritis in Europe, which undoubtedly means that Xeljanz will further expand the European market.

Lipitor and Luohuo are still in the market in China.

In 2015, Pfizer's sales in the domestic market (including public medical institutions and retail terminals, the same below) were 29.2 billion yuan, up 8.7 percentage points year-on-year. It is expected to maintain growth in 2016, with an increase of approximately 6 percentage points year-on-year.

Pfizer's domestic drug sales are mainly due to the contribution of sales of atorvastatin and amlodipine. In 2015, Pfizer's market share in the domestic market exceeded 40% in the cardiovascular and cerebrovascular fields. Followed by systemic anti-infectives and anti-tumor and immunomodulators, accounting for 26.83% and 8.37% respectively.

Adult Diaper

Adult Diaper,Thick Disposable Diapers,Wholesale Disposable Incontinence Diaper,Underwear With Dermadry

Honghu Danielle Sanitary Material Co., Ltd. , https://www.daniellecn.com